| Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring NJ Ashton, S Janelidze, N Mattsson-Carlgren, AP Binette, O Strandberg, ... Nature medicine 28 (12), 2555-2562, 2022 | 165 | 2022 |
| Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility TK Karikari, NJ Ashton, G Brinkmalm, WS Brum, AL Benedet, ... Nature Reviews Neurology 18 (7), 400-418, 2022 | 144 | 2022 |
| Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease NJ Ashton, AL Benedet, TA Pascoal, TK Karikari, J Lantero-Rodriguez, ... EBioMedicine 76, 2022 | 96 | 2022 |
| Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography J Therriault, M Vermeiren, S Servaes, C Tissot, NJ Ashton, AL Benedet, ... JAMA neurology 80 (2), 188-199, 2023 | 85 | 2023 |
| Plasma and CSF biomarkers in a memory clinic: head‐to‐head comparison of phosphorylated tau immunoassays NJ Ashton, A Puig‐Pijoan, M Milà‐Alomà, A Fernández‐Lebrero, ... Alzheimer's & Dementia 19 (5), 1913-1924, 2023 | 76 | 2023 |
| Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease JP Ferrari-Souza, PCL Ferreira, B Bellaver, C Tissot, YT Wang, DT Leffa, ... Molecular Psychiatry 27 (11), 4781-4789, 2022 | 67 | 2022 |
| Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology NJ Ashton, WS Brum, G Di Molfetta, AL Benedet, B Arslan, E Jonaitis, ... JAMA neurology 81 (3), 255-263, 2024 | 66* | 2024 |
| The accuracy and robustness of plasma biomarker models for amyloid PET positivity AL Benedet, WS Brum, O Hansson, ... Alzheimer's research & therapy 14 (1), 26, 2022 | 63 | 2022 |
| Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications F Gonzalez-Ortiz, PR Kac, WS Brum, H Zetterberg, K Blennow, TK Karikari Molecular neurodegeneration 18 (1), 18, 2023 | 51 | 2023 |
| Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models NC Cullen, S Janelidze, N Mattsson‐Carlgren, S Palmqvist, T Bittner, ... Alzheimer's & Dementia 19 (3), 797-806, 2023 | 37 | 2023 |
| A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases WS Brum, NC Cullen, S Janelidze, NJ Ashton, ER Zimmer, J Therriault, ... Nature Aging 3 (9), 1079-1090, 2023 | 35 | 2023 |
| Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability J Simrén, H Weninger, WS Brum, S Khalil, AL Benedet, K Blennow, ... Alzheimer's & Dementia 18 (10), 1988-1992, 2022 | 32 | 2022 |
| Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies L Montoliu-Gaya, AL Benedet, C Tissot, A Vrillon, NJ Ashton, WS Brum, ... Nature Aging 3 (6), 661-669, 2023 | 29 | 2023 |
| Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction Are Altered in Parkinson's Disease and Related Disorders J Nilsson, J Constantinescu, B Nellgård, P Jakobsson, WS Brum, ... Movement Disorders 38 (2), 267-277, 2023 | 21 | 2023 |
| Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies MA De Bastiani, B Bellaver, WS Brum, DG Souza, PCL Ferreira, ... Brain, Behavior, and Immunity 110, 175-184, 2023 | 20 | 2023 |
| Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer’s disease pathophysiology in cognitively unimpaired older adults DT Leffa, JP Ferrari-Souza, B Bellaver, C Tissot, PCL Ferreira, WS Brum, ... Molecular Psychiatry 28 (3), 1248-1255, 2023 | 15 | 2023 |
| Levels of Alzheimer's disease blood biomarkers are altered after food intake—A pilot intervention study in healthy adults H Huber, NJ Ashton, A Schieren, L Montoliu‐Gaya, GD Molfetta, WS Brum, ... Alzheimer's & Dementia 19 (12), 5531-5540, 2023 | 13 | 2023 |
| Effect of neprilysin inhibition on alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial WS Brum, KF Docherty, NJ Ashton, H Zetterberg, O Hansson, ... JAMA neurology 81 (2), 197-200, 2024 | 12 | 2024 |
| CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals J Simrén, WS Brum, NJ Ashton, AL Benedet, TK Karikari, H Kvartsberg, ... Alzheimer's Research & Therapy 14 (1), 192, 2022 | 11 | 2022 |
| Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study L Montoliu-Gaya, D Alcolea, NJ Ashton, J Pegueroles, J Levin, B Bosch, ... EBioMedicine 90, 2023 | 10 | 2023 |
Nicholas James AshtonUniversity of Gothenburg / King's College London在 gu.se 的电子邮件经过验证
